Rifaximin meets two late-stage study goals in treating irritable bowel syndrome-
Reports state that a new version of an irritable bowel syndrome drug, called Xifaxan (rifaximin), met its goals in two late stage studies. The trials showed rifaximin was significantly more effective than a placebo at treating non-constipation irritable bowel syndrome and also was better at reducing bloating.
Research indicates metformin with doxorubicin may kill breast cancer stem cells-
According to a study published in the Journal of Cancer Research, the diabetes drug metformin, when combined with chemotherapy drug doxorubicin, may shrink breast-cancer tumors and keep them from coming back more effectively than chemotherapy alone. Researchers reported that the combination treatment killed cancer stem cells in addition to regular cancer cells.
Study suggests drugs that lower breast cancer risk may increase risk for other cancers, clots-
According to a study published in the Annals of Internal Medicine, women who take drugs like raloxifene or tamoxifen can reduce their risk of developing invasive breast cancer by up to half, but they may be at greater risk for potentially serious blood clots. For the study, researchers assessed the risks and benefits of the drugs when used by healthy women who have never had breast cancer but are considered at greater risk for the disease.